Planned trial of ganetespib + nab-paclitaxel + gemcitabine in pancreatic cancer.
Status: Not yet recruiting
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 06 Aug 2013
Price : $35 *
At a glance
- Drugs Ganetespib (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 06 Aug 2013 New trial record
- 01 Aug 2013 Initiation of this trial is expected later in 2013 or early in 2014, according to a Synta Pharmaceuticals media release.